CD274 and non-small cell lung carcinoma: ICI therapy targeting PD1/PD-L1 and CTLA-4 has been clinically employed in progressive melanoma [4, 57], squamous cell skin cancer [58], non-small cell lung cancer [59], renal cell carcinoma [60], head and neck tumors[61], and tumors with mismatch repair defects of various tissue types[62].